Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.66 USD

41.66
3,184,816

+0.23 (0.56%)

Updated Aug 23, 2024 02:35 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

All You Need to Know About Roche Holding (RHHBY) Rating Upgrade to Strong Buy

Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

Best Momentum Stocks to Buy for August 23rd

APELY, RHHBY, and SBSI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 23, 2024.

New Strong Buy Stocks for August 23rd

RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.

Best Value Stocks to Buy for August 23rd

RHHBY, SBSI, and FCCO made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 23, 2024.

Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?

Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.

Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up

Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.

Sheraz Mian headshot

The Market's Excessive Recession Fears

We comment on the ongoing market sell-off, in addition to featuring new research reports on Johnson & Johnson (JNJ), T-Mobile (TMUS) and Marsh & McLennan (MMC) and others.

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.

Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues

Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.

Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.

Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat

Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.

Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?

On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.

Ahan Chakraborty headshot

Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?

Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View

AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.

Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised

Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.

Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised

Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.

Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline

Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.

The Zacks Analyst Blog Highlights Broadcom, Roche, Micron Technology and Moving iMage Technologies

Broadcom, Roche, Micron Technology and Moving iMage Technologies are part of the Zacks top Analyst Blog.

Sundeep Ganoria  headshot

AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.

Sheraz Mian headshot

Top Analyst Reports for Broadcom, Roche & Micron Technology

Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Roche Holding AG (RHHBY) and Micron Technology, Inc. (MU), as well a micro-cap stock Moving iMage Technologies, Inc. (MITQ).

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data

J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.

Sundeep Ganoria  headshot

Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.